Introduction
============

Most youth with HIV are now expected to live past 21 years,[@b1-hiv-2-027],[@b2-hiv-2-027] yet mortality rates are 30 times higher than for the general US pediatric population.[@b3-hiv-2-027] In 2006, in a perinatally infected cohort the mean age of death was 18 years.[@b4-hiv-2-027] Overwhelming infection due to immune system compromise contributes to morbidity.[@b4-hiv-2-027] Thus, incorporating advance care planning during the "antecedent period of decision making"[@b5-hiv-2-027] may be valuable in preparing for end-of-life (EOL) care. Quality advance care planning includes discussing death, but differs from advance directives[@b6-hiv-2-027] (ie, documenting who you want to make health care decisions for you when you can't make them for yourself, the kind of medical treatment you want or do not want). Concern about possible emotional distress has impeded families[@b7-hiv-2-027],[@b8-hiv-2-027] and providers from initiating conversations regarding EOL for teens living with a life-threatening condition.[@b9-hiv-2-027] Yet, talking about death and dying and decision-making with such teens may benefit them and their families.[@b10-hiv-2-027]--[@b12-hiv-2-027] Teens want involvement in their own EOL decisions.[@b13-hiv-2-027] Guidelines[@b11-hiv-2-027],[@b14-hiv-2-027] recommend conversations about advance care planning: 1) begin early or at diagnosis of a life-threatening condition; 2) be shared among the adolescent, family and health care provider; and 3) be routine and structured. Goals for EOL care frequently are unfulfilled, partially, because providers are concerned that talking about death and dying can provoke negative moods in the teen,[@b15-hiv-2-027] as well as families.[@b11-hiv-2-027],[@b12-hiv-2-027] Our goal was to develop/adapt a structured, safe intervention that would provide an opportunity to talk about death and dying while medically stable: planning for the worst, hoping for the best.

Guided by a community-based participatory research framework,[@b16-hiv-2-027] the Family Centered Advance Care (FACE) planning development and proximal outcomes are reported elsewhere.[@b17-hiv-2-027],[@b18-hiv-2-027] This report presents the 3-month FACE post-intervention outcomes: plans and actions, psychological adjustment, and quality of life. The FACE intervention is based on Leventhal's theory of self-regulation[@b19-hiv-2-027]--[@b21-hiv-2-027] and Folkman and Lazarus's theory of transactional stress and coping[@b22-hiv-2-027] (See [Figure 1](#f1-hiv-2-027){ref-type="fig"}), postulating that interventions can change the appraisal of an illness from a death threat to a challenge with potential for growth and mastery.

We hypothesized that at 3 months, post-intervention families in the FACE intervention study would be significantly more likely to: 1) complete an advance directive (AD); 2) maintain or have improved psychological adjustment; 3) maintain or have enhanced quality of life; and 4) maintain or decrease HIV symptom severity, compared to families in the Healthy Living Control (HLC) time-matched comparison.

Patients and methods
====================

Participants
------------

Between July 1, 2006 and May 31, 2008, 40 HIV-infected adolescents and 40 adult surrogates (n = 80) were recruited from the Children's National Medical Center (CNMC) and St. Jude Children's Research Hospital (SJCRH) outpatient adolescent HIV specialty clinics. Recruitment criteria for adolescents included: aged 14--21 years, with an available legal guardian (if under 18 years) or adult surrogate at least 21 years old who knew the adolescent's HIV status, not in foster care, no developmental delays, severe depression, suicidal or homicidal ideation, dementia or psychosis.[@b23-hiv-2-027]--[@b26-hiv-2-027] Additional family members were permitted to participate, however, their data were excluded from analyses. The FACE study was Institutional Review Board approved at both institutions. All participants provided written assent/consent.

FACE intervention and healthy living control (HLC)
--------------------------------------------------

Full details of the study methods are reported elsewhere.[@b17-hiv-2-027],[@b18-hiv-2-027] In brief, three 60--90 minute semi-structured family interview sessions were conducted by a trained/certified interviewer at weekly intervals: **Session 1**: Lyon Advance Care Planning Survey^©^ -- Adolescent and Surrogate Versions: **Session 2:** The Respecting Choices Interview^®^ **Session 3:** Completion of The Five Wishes.^©^

HLC subjects were also administered in three weekly 60--90 minute sessions and family format to control for time, attention and/or related Hawthorn effects. **Session 1:** Developmental History.[@b27-hiv-2-027] **Session 2:** Safety Tips.[@b28-hiv-2-027] **Session 3:** School and Career Planning interview.[@b29-hiv-2-027]

Outcome measures
----------------

**Five Wishes^©^** (Towey and Aging with Dignity) is a legal document that facilitates expression of treatment preferences, if they were unable to communicate their wishes and includes the selection of a surrogate decision-maker. It can also serve as a tool to facilitate the participation of adolescents under age 18,[@b30-hiv-2-027] but must be signed by their parent/legal guardian to be legally sufficient.

**Statement of Treatment Preferences**[@b31-hiv-2-027] expresses values and goals related to future decision making regarding frequently occurring scenarios common to individuals with complications of AIDS.[@b32-hiv-2-027] It was used to document specific treatment preferences of patients and their surrogates' understanding of what the patient would want. Patients and surrogates chose one of three options, "to continue all treatment and keep fighting," "to stop all treatment to prolong my life," and "don't know."

**Beck Anxiety Index** (BAI)[@b24-hiv-2-027] is a 21-item measure of anxiety rated on a 4-point Likert scale of symptoms over the past week. The BAI has demonstrated adequate reliability and validity to clinically assess anxiety in individuals aged 17 to 80. We extended downward to age 14 to allow for consistency of data collected by a single measure of anxiety.

**Beck Depression Inventory-II**[@b25-hiv-2-027] is a 21-item scale self-report measure to assess presence of symptoms of depression over the past two weeks on a 4-point Likert scale for adolescents \>13 years of age.

**The Pediatric Quality of Life Inventory^™^** **4.0**[@b33-hiv-2-027]--[@b35-hiv-2-027] is a 23-item modular measure of health-related quality of life in children and adolescents. Four dimensions of functional quality of life (physical, emotional, social, school) are assessed. It has the strongest norms, validity, and reliability of the measures available. Norms exist for up to age 18.9 years, which was extended upward to allow for one assessment measure across participants.

**General Health Assessment for Children**[@b36-hiv-2-027] is a self-report measure for adolescents aged 12--20 years. The HIV-related symptom subscale was used to assess the degree of distress caused by HIV-related physical symptoms. It is comprised of 18 items rated on a six-point Likert scale ("Not at All" to "Extremely").

Measures were administered separately to both the adolescent and surrogate, at baseline and at the 3-month post-intervention follow-up.

**Stage of Illness** was measured by the CDC (Centers for Disease Control and Prevention) classification system in place at the time of the study.[@b37-hiv-2-027]

Study design/data collection
----------------------------

Adolescent/surrogate dyads were randomly assigned to one of two study groups, FACE versus HLC. Randomization utilized permuted block design, based on study site, to ensure the same numbers would be recruited to FACE and HLC. All participants were given a brochure with information on advance care planning and received standard of care. Follow-up data were collected face-to-face at 3-months post-intervention with two exceptions. A research assistant, not the facilitator, administered follow-up questionnaires orally to control for literacy. Progress of participants through the trial is illustrated in [Figure 2](#f2-hiv-2-027){ref-type="fig"}.

Statistical analysis
--------------------

To assess whether the FACE intervention participants established an advance directive, medical charts were reviewed for documented completion.

Before we implemented parametric analyses, we evaluated the normality and variance homogeneity assumptions and when necessary implemented data transformations to ensure the data met these assumptions. Following analyses involving data transformations, the results were back transformed to return the estimates to their original scale and units. In this event, adjusted means are reported which also control for baseline levels of scores.

To evaluate changes in psychological adjustment and quality of life, ANCOVA (analysis of covariance) was used to estimate and compare group means, with 95% confidence intervals, by study group and assess the effect of the two groups. Each estimate was derived controlling for baseline anxiety and depression scores, as well as any covariates found in preliminary analyses to differ between groups. The slope coefficient for group was used to estimate the magnitude of any differences. A *t*-test was employed to assess statistical significance.

In secondary analyses, logistic regression models were used to test for a trend in the outcome based on the level of severity of illness using CDC criteria.[@b37-hiv-2-027] It was unnecessary to code for intervention exposure, because all subjects attended 100% of Sessions 1--3. Estimates were derived separately for surrogate and adolescent. However, when possible, overall estimates were derived by treating the dyad as a cluster, again controlling for baseline levels, as well as any covariates found in preliminary analyses to differ between groups.

Results
=======

Sample characteristics
----------------------

Randomization produced an acceptable balance respecting group assignment by sample characteristics at baseline.[@b17-hiv-2-027] Of eligible families, 97% chose to participate. As planned, 40 dyads were randomized. However, two dyads were excluded from analyses due to withdrawal from the study prior to the start of Session 1. See [Figure 2](#f2-hiv-2-027){ref-type="fig"}. Data analyses were based on 38 dyads, using an intent-to-treat design, which included the 2 misallocated dyads. The characteristics of these 38 adolescents are presented in [Table 1](#t1-hiv-2-027){ref-type="table"}. There were no adverse events.

Plans and actions
-----------------

FACE adolescents completed the Five Wishes^©^ with their families at a higher rate than the HLC adolescents (90% versus 11%, *P* \< 0.001; [Table 2](#t2-hiv-2-027){ref-type="table"}). At Baseline, one adolescent in the FACE group previously completed an AD and 5 were unsure whether they had. At 3-month post-intervention uncertainty was resolved. Five Wishes^©^ completion did not significantly differ by gender, race, ethnicity, education, employment status, CDC stage of illness, number of guardians present, length of time with known diagnosis or age at diagnosis. However, teens whose surrogates were not biological family members (n = 8/10; 80%) were more likely to complete the Five Wishes^©^ than those whose surrogates who were biological relatives (11/28; 40%, *P* = 0.031).

Decision to stop extraordinary treatment
----------------------------------------

On the Statement of Treatment Preferences the majority of adolescents chose to continue all treatments, regardless of quality of life. Ten percent of adolescents in Situation 1, 26% in Situation 2, and 24% in Situation 3 chose to discontinue extraordinary treatment. FACE adolescents appeared to be no more likely than HLC adolescents to discontinue treatment across the three situations, but the absence of statistical significance in this small sample is not absence of an effect. See [Table 2](#t2-hiv-2-027){ref-type="table"}. Non-African-American adolescents were significantly more likely to choose discontinue treatment (*P* = 0.026). A trend emerged for non-African-American adolescents to be more likely to discontinue treatment under Situation 2 (*P* = 0.060), if they were to become physically disabled and require nursing home care. No associations reached significance between the three Situations by gender, education, employment status, age, length of time known diagnosis or age learned HIV status.

Psychological adjustment
------------------------

FACE adolescents who talked about their own prospective death and dying with their families in facilitated conversations by a trained facilitator were no more depressed or anxious than HLC adolescents at 3-months post-intervention ([Table 3](#t3-hiv-2-027){ref-type="table"}). Surrogates in the FACE group demonstrated slight increases in depressed and anxious mood compared to controls at 3-months post-intervention, controlling for baseline levels. However, increases were not clinically or statistically significant, but in minimal ranges and could be due to chance. Baseline levels of depression and anxiety predicted depression (adolescents, *P* = 0.002; surrogates, *P* \< 0.001) and anxiety (adolescents, *P* = 0.003; surrogates *P* \< 0.001) at 3-months post-intervention. Overall, adjusted mean levels of adolescent and surrogate depression and anxiety ([Table 3](#t3-hiv-2-027){ref-type="table"}) at 3-month post-intervention fell in the minimal clinical range. Depression and anxiety at 3-month post-intervention, controlling for baseline, did not differ significantly by gender, race, ethnicity, education, employment status, age at diagnosis, length of time with known diagnosis, family type or number of guardians present. Adolescents assigned to the intervention had statistically significantly higher depressed mood compared to controls at baseline, although mood levels were clinically insignificant in the minimal range.

Quality of life
---------------

Quality of life as measured by the PedsQL^™^ Total score was maintained for adolescents in both FACE and HLC and there were not significant differences by group or on any of the subscales ([Table 4](#t4-hiv-2-027){ref-type="table"}).

However, surrogates' perception of their adolescents' Total quality of life was significantly lower for surrogates in the FACE versus HLC group (*P* = 0.032) at 3-months, controlling for baseline levels. FACE surrogates rated their adolescents as having poorer *school* quality of life at 3-months post-intervention (66.9 versus 80.0, *P* = 0.011) and poorer *emotion* quality of life (74.8 versus 85.7, *P* = 0.029), compared to HLC surrogates. The *physical* and *social* subscale scores were not significantly different by group, controlling for baseline levels.

Quality of life -- HIV specific symptoms
----------------------------------------

On the GHAC trends towards more HIV-specific symptoms emerged in FACE vs HLC adolescents for the following symptoms (See [Table 5](#t5-hiv-2-027){ref-type="table"}): rash or itching; fatigue or weakness; and trouble sleeping. However, the scores reflect very low levels of symptoms, if examined using the midpoint cut-off for reporting symptoms which distressed them, moderately, very much or extremely. There were no statistically significant differences between FACE and HLC teens for any other HIV related symptoms 3-months post-intervention. There also was no relationship between Treatment Preferences and symptom score (*P* = 0.39).

In secondary analysis using a regression model examining all adolescents regardless of treatment arm, those in CDC Category B (symptomatic, not AIDS) had lower physical scores (more symptoms) than those in Category A (asymptomatic) or C (AIDS) (*P* = 0.005) and they scored higher on Total Symptoms (*P* = 0.015).

Discussion
==========

Using a rigorous randomized 2-arm design and intent-to-treat analysis, the FACE intervention demonstrated that advance care planning can be safely administered to HIV+ teens, ie, did not cause significant emotional distress or adverse events. FACE prepared surrogate decision makers for their role in EOL discussions and treatment decisions.

Our study challenges earlier findings[@b38-hiv-2-027]--[@b47-hiv-2-027] with 100% of our primarily African-American FACE group completing an advance directive. The fact that several families spontaneously requested an extra copy of the Five Wishes^©^ to complete for themselves suggests this outcome was not a result of the Hawthorne Effect (desire to please the researcher). Our results are consistent with a report by Washington, who in a study of African-American primary caregivers who made decisions about EOL care, found strong support for hospice care.[@b48-hiv-2-027]

Participating in the FACE intervention did not influence decisions to discontinue treatment. Our goal was to safely assist adolescents with HIV/AIDS to make decisions with their families about their EOL preferences, while still cognitively intact.[@b49-hiv-2-027]--[@b51-hiv-2-027] People sometimes change their AD as the disease progresses, for example, deciding to "Allow a Natural Death," rather than to continue aggressive treatment(s). Thus, EOL care decision making is best under-stood as an ongoing process, rather than a one-time event, and should be revisited.[@b52-hiv-2-027]--[@b57-hiv-2-027]

Consistent with earlier adult studies[@b44-hiv-2-027],[@b45-hiv-2-027],[@b58-hiv-2-027]--[@b61-hiv-2-027] African-American adolescents in our cohort preferred to continue all treatments at EOL at rates significantly higher than non-African-American adolescents, however, because of our small sample size this result may not be stable. This finding differs from that of Hinds and colleagues[@b62-hiv-2-027] who reported race did not influence DNR (do not resuscitate) status in a pediatric oncology sample. This difference could be due to the timing of decision making, which in the Hinds study was during what Hansen[@b5-hiv-2-027] calls the "central period" of decision making (where EOL is eminent), rather than the "antecedent period" as was done in our study. Our African-American families were willing to think and talk about EOL issues and were prepared for their role as decision-makers.[@b17-hiv-2-027],[@b18-hiv-2-027]

FACE achieved rates of recruitment in excess of those reported in adults in which only 30%--47% of eligible patients participated in EOL studies.[@b63-hiv-2-027]--[@b66-hiv-2-027] Nevertheless, 54% of potential participants approached prior to screening for eligibility, declined to participate. Dyadic/family studies pose a challenge as sometimes the patient wants to participate, but the family member does not have time, wants to protect the patient, or is uninterested.[@b67-hiv-2-027]

Several factors may explain the success of the FACE intervention. First, we integrated processes identified with successful HIV interventions,[@b68-hiv-2-027]--[@b70-hiv-2-027] specifically, community-based participation in development and adaptation to ensure cultural sensitivity and to reduce health disparities.[@b16-hiv-2-027],[@b17-hiv-2-027],[@b71-hiv-2-027],[@b72-hiv-2-027] Second, we used a competency-based program to ensure consistency in the delivery of the intervention as measured by two components: 1) facilitator certification and 2) patient and family ratings of quality of communication, consistent with the recommendations of Dickens.[@b72-hiv-2-027] Third, the high rate of retention suggests participants were highly motivated to seek education and improve long-term care. Fourth, FACE was highly family-centered. Finally, research assistants were hired and retained only if they committed to flexibility in scheduling sessions and if successfully certified (Respecting Choices^®^ interview).

In contrast to Bakitas and colleagues,[@b63-hiv-2-027] we did not find improvements in quality of life or mood for the intervention group, rather healthy levels of mood and quality of life were maintained. Floor effects for mood and ceiling effects for quality of life limited the power to detect differences, and differences that we found were within healthy ranges and therefore not clinically significant. The reason(s) higher levels of depressed mood were found at baseline for adolescents randomly assigned to FACE versus HLC are unclear. Baseline assessment occurred before randomization, so assignment to the intervention group did not impact mood.

Unexpectedly, FACE surrogates perceived their adolescents' school and emotional quality of life was lower compared to HLC surrogates. This may reflect increased knowledge of school related and emotional problems for their teens that emerged during the facilitated conversation. Also, FACE surrogates reported more sadness and anxiety at 3-month post-intervention, than FACE adolescents who reported less compared to baseline levels. Although the changes were not clinically or statistically significant, they suggest that adolescents may have found talking about their own death and dying less anxiety provoking and sad than their families did. This finding needs further study.

Conclusion
==========

The FACE results begin to fill the gap on ethnocultural factors that influence EOL decision making and preferences among HIV-positive adolescents, who demonstrated a willingness to discuss difficult and emotionally-laden issues with their surrogate decision makers and complete advance directives, potentially "breaking the ice" for future EOL conversations. Going beyond measuring the effect of communication on satisfaction, we studied outcomes related to advance care planning, quality of life and mood using standardized measures. The FACE results suggest that research into this sensitive area is safe. Probable benefits at the time of dying for teens and families, or after death for families, remain to be demonstrated in future studies.
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![Transactonal model of coping with stress.\
**Notes:** Proximal program mediators are shown in shaded areas.\
Plans and Actions = statement of treatment preferences and completion of Five Wishes^©^ advance directive.\
Psychological Adjustment = Symptoms of depressed or anxious mood as measured by the Beck Depression Inventory II or the Beck Anxiety Inventory.\
Quality of Life = Total, School, Emotion, Physical and Social quality of life as measured by PedsQL™; HIV Specific Symptoms as measured by the General Health Assessment for Children.\
**Abbreviations:** A, adolescent; F, family; FACE, Family Centered Advance Care.](hiv-2-027f1){#f1-hiv-2-027}

![Flow of participants through each stage of the trial.\
**Notes:** \*Kept in analysis, per intent-to-treat design, as if received allocated condition; \*\*n = 1 randomized intervention adolescent became psychotic & ineligible before Session 1; \*\*\*n = 1 randomized adolescent control was shot & withdrew from study before Session 1.](hiv-2-027f2){#f2-hiv-2-027}

###### 

3-month post-intervention characteristics for family centered (FACE) and healthy living control (HLC) adolescents with HIV/AIDS (n = 38)

  ----------------------------------------------------------------------------------
  Adolescent characteristics                   FACE intervention\   HLC group\
                                               n = 20               n = 18
  -------------------------------------------- -------------------- ----------------
  Age (in years)                                                    

   Mean (±SD)                                  16.65 (±2.11)        16.58 (±2.38)

  Gender                                                            

   Males                                       8 (40%)              7 (39%)

   Females                                     12 (60%)             11 (61%)

  Race/Ethnicity                                                    

   Black/African American                      17 (94%)             18 (90%)

   Non-African American                        1 (6%)               2 (10%)

  Mode of HIV Transmission                                          

   Perinatal infection                         15 (75%)             11 (61%)

   Behavioral infection                        5 (25%)              7 (39%)

  CDC classification[@b1-hiv-2-027]                                 

   A 1--3 (asymptomatic)                       5 (25%)              11 (61%)

   B 1--3 (symptomatic)                        6 (30%)              5 (28%)

   C 2--3[@b2-hiv-2-027] (AIDS)                9 (45%)              2 (11%)

  Education                                                         

   No High School Diploma/in HS                12 (60%)             10 (56%)

   HS or GED equivalent                        4 (20%)              6 (33%)

   Some college/no bachelors                   4 (20%)              2 (11%)

  Income                                                            

   ≤ Federal poverty line                      7 (35%)              6 (33%)

   100%--200% of Federal poverty line          1 (5%)               3 (17%)

   201%--300% of Federal poverty line          4 (20%)              4 (22%)

   \>300% of Federal poverty line              6 (30%)              3 (17%)

   Unknown                                     2 (10%)              2 (11%)

  Housing status                                                    

   Permanently housed                          18 (90%)             17 (94%)

   Unstable living arrangement                 2 (10%)              1 (6%)

  Sexual orientation                                                

   Heterosexual                                17 (85%)             15 (83%)

   Homosexual                                  1 (5%)               1 (5.6%)

   Bisexual                                    2 (10%)              1 (5.6%)

   Don't know                                  0 (0%)               1 (5%)

  Marital status                                                    

   Single                                      19 (95%)             17 (94%)

   Married/Living                                                   

   Together                                    1 (5%)               1 (6%)

  Length of time known diagnosis (in months)                        

   Mean (SD)                                   102.32 (±64.14)      80.27 (±66.16)

   Range                                       11--220              3--207

  Age learned HIV+ (in years)                                       

   Mean (SD)                                   9.42 (±5.35)         11.5 (±5.21)

   Range                                       0--18                0--18
  ----------------------------------------------------------------------------------

**Notes:**

Data are from the old Centers for Disease Control and Prevention Classification system.[@b37-hiv-2-027]

No patient had category C1.

**Abbreviations:** CDC, Centers for Disease Control and Prevention; (1992); GED, general educational development; FACE, Family Centered Advance Care planning intervention; HLC, healthy living control for time and attention, matched comparison group; SD, standard deviation.

###### 

3-month post-intervention outcomes: plans and actions

  Outcomes                              FACE                                                        HLC       *P*[+](#tfn4-hiv-2-027){ref-type="table-fn"} value
  ------------------------------------- ----------------------------------------------------------- --------- ----------------------------------------------------
  Completed Five Wishes or other AD     19[a](#tfn8-hiv-2-027){ref-type="table-fn"} (95%)           2 (11%)   \<0.001[\*](#tfn9-hiv-2-027){ref-type="table-fn"}
  Statement of Treatment Preferences:   Stop all efforts[+](#tfn4-hiv-2-027){ref-type="table-fn"}             
  Situation \#1                         3 (15%)                                                     1 (6%)    0.187[a](#tfn8-hiv-2-027){ref-type="table-fn"}
  Situation \#2                         5 (25%)                                                     5 (28%)   1.000[a](#tfn8-hiv-2-027){ref-type="table-fn"}
  Situation \#3                         6 (30%)                                                     3 (17%)   0.528[a](#tfn8-hiv-2-027){ref-type="table-fn"}

**Notes:** "To stop all efforts to keep me alive (For me quality of life is more important than length of life). This includes such treatments as CPR, blood transfusions, kidney dialysis and tube feedings.

1\. If I have serious complications from AIDS, such as an overwhelming infection or pneumonia, so that I was facing a long hospital stay, with many medical treatments AND my chance of living through this complication is low (for example, only 5 out of 100 kids will live), I would choose the following: (Whatever my choice, I want to be kept as comfortable as possible).

2\. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living through this complication, but it was expected that I would never be able to walk or talk again, and I would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).

3\. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living, but it was expected that I would never know who I was or who I was with and would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).

**Notes:** Data are frequencies. 1-sided Fisher Exact Test. 1 patient completed Five Wishes outside of one month post session window for protocol. No significant differences by perinatal vs behavioral transmission for completing advance directive, *P* = 0.284.

Significant at the *P* = 0.05 level.

**Abbreviations:** CPR, cardiopulmonary resusication; FACE, Family Centered Advance Care Planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC, healthy living control.

###### 

3-month post-intervention outcomes: psychological adjustment by treatment group controlling for baseline levels

  Outcomes                                                                                                                               FACE (n = 40)       HLC (n = 36)        P^+^ value
  -------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------
  **BAI adjusted mean scores with upper and lower 95% confidence intervals (Range 0--63; 0 to 7** = **minimal anxiety)**                                                         
  Adolescent                                                                                                                                                                     
   Baseline                                                                                                                              2.76 (1.38--4.60)   1.38 (0.44--2.84)   0.170
   3 month post-intervention                                                                                                             2.48 (1.14--4.34)   1.06 (0.24--2.45)   0.149
  Surrogate's own mood                                                                                                                                                           
   Baseline                                                                                                                              1.64 (0.62--3.14)   2.51 (1.14--4.41)   0.395
   3 month post-intervention                                                                                                             2.48 (1.20--4.22)   2.35 (1.06--4.15)   0.901
  **BDI-II adjusted mean scores^\*\*^with upper and lower 95% confidence intervals (range 0--63; 0--13** = **minimal depressed mood)**                                           
  Adolescent                                                                                                                                                                     
   Baseline                                                                                                                              7.8 (4.73--11.69)   1.27 (0.22--3.17)   0.001^\*^
   3 month post-intervention                                                                                                             5.06 (2.57--8.39)   3.43 (1.35--6.45)   0.432
  Surrogate's own mood                                                                                                                                                           
   Baseline                                                                                                                              2.0 (0.66--4.09)    3.65 (1.62--6.50)   0.261
   3 month post-intervention                                                                                                             2.73 (1.26--4.77)   3.29 (1.57--5.65)   0.676

**Abbreviations:** BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory; 2nd Edition. Higher scores represent higher symptom levels. FACE, Family Centered Advance Care planning; HLC, healthy living control.

###### 

3-month post-intervention outcome: quality of life: PedsQL™ adjusted mean scores with 95% confidence intervals (ci upper and lower limits), controlling for baseline levels

  Outcomes                                             FACE                   HLC                    P[+](#tfn13-hiv-2-027){ref-type="table-fn"} value
  ---------------------------------------------------- ---------------------- ---------------------- ---------------------------------------------------
  Adolescent                                                                                         
   TOTAL                                               338.5 (321--355)       345.6 (327.3--363.1)   0.568
   Physical                                            93.1 (89.4--96.6)      93.8 (91.3--96.3)      0.692
   School                                              75.0 (68.4--82.0)      77.7 (70.7--85.2)      0.589
   Emotional                                           82.0 (74.8--88.6)      82.5 (74.4--90.0)      0.921
   Social                                              90.3 (86.5--93.9)      92.0 (88.6--95.2)      0.297
  Surrogate perception of adolescent quality of Life                                                 
   TOTAL                                               324.8 (308.4--340.4)   349.3 (333.4--364.6)   0.032[\*](#tfn12-hiv-2-027){ref-type="table-fn"}
   Physical                                            92.3 (89.3--95.1)      93.0 (89.7--96.1)      0.692
   School                                              66.9 (60.0--74.1)      80.0 (72.1--88.3)      0.018[\*](#tfn12-hiv-2-027){ref-type="table-fn"}
   Emotion                                             74.8 (67.2--81.6)      85.7 (78.9--92.0)      0.029[\*](#tfn12-hiv-2-027){ref-type="table-fn"}
   Social                                              91.0 (88.0--93.8)      92.7 (89.2--95.9)      0.297

**Notes:**

Significant at *P* = 0.05.

All *P* values control for baseline using a *t*-test to assess significance. Range of subscale scores is 0 to 100. Higher scores represent better quality of life.

**Abbreviations:** FACE, Family Centered Advance Care planning; HLC, healthy living control.

###### 

3-month post-intervention outcomes: quality of life-HIV specific symptoms: general health assessment for children HIV symptoms. Percentage of adolescents reporting moderately, very much or extremely distressed by symptom at 3-month post-intervention controlling for baseline levels of symptoms

  ----------------------------------------------------------------------------------------------------------------------------------
  HIV specific symptoms                     FACE intervention\   HLC comparison\   *P* value
                                            n = 20               n = 18            
  ----------------------------------------- -------------------- ----------------- -------------------------------------------------
  Physical/bodily pain                      5%                   0%                0.210

  Coughing/Wheezing                         10%                  0%                0.604

  Nausea/vomiting                           5%                   0%                0.737

  Skin problems (rash, itching, etc)        5%                   0%                0.063[+](#tfn15-hiv-2-027){ref-type="table-fn"}

  Fatigue                                   0%                   5%                0.095[+](#tfn15-hiv-2-027){ref-type="table-fn"}

  Feeling dizzy/lightheaded                 5%                   0%                0.178

  Fever/night sweats/shaking/chills         5%                   0%                0.737

  Loss of appetite                          5%                   0%                0.663

  Trouble sleeping                          0%                   0%                0.058[+](#tfn15-hiv-2-027){ref-type="table-fn"}

  Eye trouble/problems with vision          0%                   5%                0.734

  Headaches                                 5%                   0%                0.342

  Dry or painful mouth/trouble swallowing   0%                   0%                1.0

  Chest pain or tightness                   5%                   0%                1.0

  Difficulty breathing or catching breath   0%                   0%                0.656

  Runny nose/sinus trouble                  10%                  0%                0.479

  Muscle aches/joint or bone pain           0%                   0%                0.232

  Pain, numbness or tingling                0%                   0%                0.792

  Overall discomfort                        0%                   0%                0.697
  ----------------------------------------------------------------------------------------------------------------------------------

**Notes:** All *P* values control for baseline using a *t*-test to assess significance at the 0.05 level.

**Abbreviations:** FACE, Family Centered Advance Care planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC, healthy living control.
